Moderna, Inc. vs National Energy Services Reunited Corp Ordinary Shares — how do they compare? Moderna, Inc. trades at $221.9 (market cap $90.35B), while National Energy Services Reunited Corp Ordinary Shares trades at $19.5 (market cap $1.97B). The key difference: Moderna, Inc. is far larger — about 45.9× National Energy Services Reunited Corp Ordinary Shares's market cap, and Moderna, Inc. is trading nearer its 52-week high, National Energy Services Reunited Corp Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and National Energy Services Reunited Corp Ordinary Shares for 0 Days on average.
| MRNA | NESR | |
|---|---|---|
Market Cap | $90.35B | $1.97B |
Volume | 16,579,584 | 4,629,858 |
Sector | Health | Energy |
52-Week High | $226.30 | $36.31 |
52-Week Low | $22.36 | $10.41 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $86.50B | $2.10B |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal and recent Nasdaq-100 inclusion driving momentum. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with a net income margin of -142.58% and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock's 500% rally in 2026 has pushed valuations to elevated levels with a P/S of 38.5, creating divergence between technical strength and financial performance.
The outlook remains polarized with Nasdaq inclusion providing institutional support but valuation concerns capping upside. Investment opportunity lies in the cancer vaccine pipeline, while risks include sustained profitability challenges and competitive pressures. Analyst consensus at $115.70 suggests significant downside from current levels, with only 28% recommending buy ratings amid ongoing operational cash flow deficits.
NESR trades at $21.03, up 0.62% today, with neutral technical signals and strong fundamental momentum. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations by 25%. Revenue growth remains robust, driven by Middle East operations including the Jafurah gas field expansion. Analyst sentiment is overwhelmingly positive with 83% buy ratings and a consensus price target of $41.80, representing nearly 100% upside potential.
The outlook remains favorable with projected revenue growth to $1.6B in 2026 and net profit doubling to $93M. Key risks include execution pressure from premium valuation and regional geopolitical uncertainties. The recent lithium extraction deal with Saudi Aramco provides additional growth optionality, though capital demands remain elevated. Current levels offer attractive entry for growth-oriented investors despite technical neutrality.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →National Energy Services Reunited Corp (NESR) is a Houston-based oilfield services company that provides drilling, evaluation, and production services, including hydraulic fracturing, cementing, coiled tubing, and directional drilling, to oil and gas operators. It focuses primarily on markets across the Middle East, North Africa, and Asia Pacific.
Read more on NESR →